Stock Performance and Market Context
On the day in question, the stock opened sharply lower with an 11.91% gap down, touching an intraday low of Rs. 3,950.5, which represents its lowest price ever recorded. Despite this, the stock outperformed its sector by 0.35% during the trading session, closing with a day change of -1.61%, compared to the Sensex’s decline of -0.88%. Over the last two trading days, Sanofi Consumer Healthcare India Ltd has recorded a cumulative return of -3.57%, continuing a downward trajectory.
Examining moving averages, the stock price currently sits above its 5-day, 20-day, and 50-day averages but remains below the 100-day and 200-day moving averages, indicating mixed short-term momentum against longer-term trends.
Relative Performance Over Time
Over the past year, the stock has declined by 3.03%, underperforming the Sensex, which gained 10.08% in the same period. The year-to-date performance also shows a negative return of 2.52%, though this is less severe than the Sensex’s 5.45% decline. Over three months, the stock fell 4.58%, slightly better than the Sensex’s 5.36% drop. Longer-term returns are flat, with zero growth over three and five years, contrasting sharply with the Sensex’s robust gains of 36.77% and 60.19% respectively. The ten-year performance remains unchanged, while the Sensex surged 232.36%.
This week's disclosed pick, a Large Cap from NBFC, comes with precise Target Price and analysis. Check if you're positioned right for this opportunity!
- - Precise target price set
- - Weekly selection live
- - Position check opportunity
Valuation and Financial Metrics
The company’s valuation metrics highlight a premium pricing environment. Sanofi Consumer Healthcare India Ltd carries a Price to Book Value ratio of 39.8, which is considered very expensive relative to industry norms. The Return on Equity (ROE) stands at a notably high 91.4%, reflecting strong management efficiency in generating shareholder returns. However, this elevated ROE is accompanied by a PEG ratio of 2.6, indicating that the stock’s price growth may be outpacing earnings growth.
Operating profit has grown at an annualised rate of 11.72% over the past five years, a moderate pace that has not translated into commensurate stock price appreciation. Despite a 17% increase in profits over the last year, the stock’s returns have remained negative, suggesting a disconnect between earnings growth and market valuation.
Recent Quarterly Results
The company reported very positive quarterly results in December 2025, with net sales reaching a quarterly high of Rs. 251 crore. Profit before depreciation, interest, and tax (PBDIT) also hit a peak at Rs. 89.8 crore, while profit before tax excluding other income (PBT less OI) stood at Rs. 85.9 crore. These figures represent the highest quarterly performance to date, and the company has declared positive results for two consecutive quarters, signalling operational stability in the near term.
Balance Sheet and Institutional Holding
Sanofi Consumer Healthcare India Ltd maintains a conservative capital structure with an average Debt to Equity ratio of zero, indicating no reliance on debt financing. This low leverage reduces financial risk and supports sustainable operations. Institutional investors hold a significant 20.16% stake in the company, reflecting confidence from entities with extensive analytical resources and a long-term perspective on fundamentals.
Sector and Market Grade Assessments
The company operates within the Pharmaceuticals & Biotechnology sector, which has experienced varied performance in recent months. Sanofi Consumer Healthcare India Ltd’s Mojo Score stands at 48.0, with a Mojo Grade of Sell as of 28 Oct 2025, downgraded from Hold. The Market Cap Grade is rated 3, indicating a mid-tier market capitalisation relative to peers. These assessments reflect the stock’s current standing within the broader market and sector context.
Sanofi Consumer Healthcare India Ltd or something better? Our SwitchER feature analyzes this small-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Summary of Challenges
While the company demonstrates strong management efficiency and solid quarterly results, the stock’s all-time low price reflects broader market concerns about its valuation and growth trajectory. The flat returns over three and five years, combined with a premium Price to Book ratio and a PEG ratio above 2, suggest that the market is pricing in limited upside relative to the current price level. The stock’s recent underperformance relative to the Sensex and BSE500 indices further underscores the challenges faced in delivering sustained shareholder value.
Conclusion
Sanofi Consumer Healthcare India Ltd’s stock reaching an all-time low of Rs. 3,950.5 marks a significant development within the Pharmaceuticals & Biotechnology sector. Despite positive quarterly earnings and a strong balance sheet, the stock’s valuation metrics and relative performance indicate a cautious market stance. The company’s high ROE and zero debt position highlight operational strengths, yet these have not translated into price appreciation over the medium to long term. This situation reflects a complex market environment where valuation and growth expectations remain key factors influencing investor sentiment.
Only Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Start Today
